LexShares Case #357: The Favorable View
A small pharmaceutical company spent eleven years suing a Fortune 50 drugmaker over a broken license agreement. Every fact I checked before investing turned out to be true. Three arbitrators rejected the claim anyway, and there is nobody to appeal to.
The Numbers
| Invested | $75,000 |
| Returned | $0 |
| Net Loss | ($75,000) |
| MOIC | 0.00x |
| IRR | -100% |
| Holding Period | 8 years, 2 months |
| Claimed Damages | $900,000,000+ |
The Case
In July 2008, a clinical-stage pharmaceutical company licensed its lead product to the animal-health division of a Fortune 50 drugmaker. The product treated bovine mastitis — an udder infection that is the most expensive routine disease in dairy farming and one of the biggest reasons antibiotics get used on livestock. The licensee got the exclusive right to develop, market and sell it worldwide. The biotech got a share of the revenue.
The licensee never sold it.
Over roughly five years, according to the biotech, the licensee did four things wrong:
| Alleged breach | Detail |
|---|---|
| Refused to meet | Would not convene the joint advisory board the agreement required, for about two and a half years |
| Botched a study | Ran the wrong analysis on a clinical trial and filed the erroneous version with regulators after being told it was wrong |
| Leaked the IP | Disclosed the biotech’s confidential intellectual property to third parties without consent |
| Never promoted it | Made no good-faith commercialization effort, which the contract obliged it to make |
In February 2014 the licensee terminated the agreement. A year later it went to federal court first, asking for a declaration that it owed nothing. The biotech counterclaimed for more than $900 million in lost profits — the money it said it would have made if the product had been commercialized properly.
I funded $75,000 of that counterclaim in May 2018, three years into the litigation.
Why I Invested
Three things were true in May 2018, and all three still look right today.
The breaches were documented, not inferred. Not “they didn’t try hard enough” — specific refused meetings, a specific misfiled study, a specific IP disclosure. This is the kind of claim that doesn’t evaporate under discovery.
The claims had already survived two rounds of attack. A motion to dismiss denied in February 2016, and an appeal denied in April 2017 that affirmed the claims in their entirety. Two courts had looked at this and let it proceed.
The defendant could pay. A Fortune 50 pharmaceutical company. No collection risk, no bankruptcy risk, no enforcement problem — the failure mode that had already cost me money on other cases.
What I never analyzed was damages. The whole case was a claim for $900 million in profits on a product that was never sold. There was no revenue history, no market share, no comparable launch — just two sets of expert projections about a business that never existed. I had no view on whose model was better, and I invested anyway.
Seven Years of Updates
The news that came in over the next five years was, on its face, encouraging.
September 2019: fact discovery closed. Nothing adverse surfaced. The documents backed the story.
August 2023: clinical trials with a major dairy group confirmed the product actually worked — it measurably cut antibiotic use. The lost profits were for something real, not a science-project drug that would have failed anyway.
Both were about the same question: whether the biotech had a legitimate grievance. It did. Neither said anything about whether a fact-finder would put $900 million on it.
Two mediations failed, in January 2022 and June 2024. Both came after full discovery, when each side had read the other’s damages case — including the half of it I never examined. A defendant with the balance sheet to pay anything, twice declining to pay something, is that defendant’s valuation of the claim.
Out of Court and Into Arbitration
In February 2025, after the second mediation failed, the parties agreed to pull the dispute out of federal court and send it to private arbitration before a three-member panel at one of the major international arbitration bodies.
Final and binding. That institution offers an optional appellate tier — a second panel that can review the first one’s decision for legal error. The parties did not elect it.
For a funder, no appeal is genuinely good news. Appeals are what kill returns in this asset class: eighteen months of delay bolted onto a case that has already run a decade, applied to a multiple that was never big enough to survive the wait. A decision nobody can appeal is a decision that pays quickly.
The clause is symmetric, though. No appeal also means no appeal when you lose. In February 2025 my $75,000 stopped being a stake in a federal case with a jury, a judge, a public record and appeal rights, and became a stake in one private decision by three people that nothing could reverse.
The parties agreed to this between themselves, seven years after I funded. I learned about it in an update after the fact.
It also cost me the docket. I had followed this case for seven years on PACER — every filing, every order, every hearing date, readable by anyone who cared to look. Private arbitration has none of that. After February 2025 there was nothing to check and nothing to read, and the platform’s updates became the only thing I knew about my own investment. That turned out to matter.
The Hearing and the Award
The arbitration moved fast by litigation standards. A nine-day evidentiary hearing in January 2026 with fact witnesses, expert witnesses and extensive documents. Post-hearing briefs in the spring. Closing arguments on May 1, 2026.
Counsel’s read afterward, relayed to investors, was that the hearing had gone very well and they remained confident.
Under the institution’s rules the award was due within about 60 days of closing — roughly July 1. July came and went. So did August. I wrote to the platform on September 9 asking where the award was.
The reply came on September 11:
On July 28, 2026, the tribunal issued its Final Award in favor of the defendant and rejected the biotech’s claims.
The award had been issued six weeks earlier. The platform’s covering note described the decision as having come down “~10 days ago”; the award itself was dated July 28. Both the platform and the claimant’s own counsel described the outcome as unexpected.
$75,000 to $0.
Why the panel ruled that way, I don’t know. The award hasn’t been shared with investors and the platform said it was still waiting on counsel’s written analysis to understand the reasoning. So I can’t tell you whether the tribunal found no breach, or breach without causation, or damages it thought unproven. That’s worth stating plainly before the lessons, because the tempting version of this story — I was right on the merits and unlucky on the number — is one I have no evidence for. What I can say is narrower and less flattering: I never had a view on the number at all.
Why There Is No Appeal
The platform’s note said the claimant was “reviewing whether there are grounds for appeal.” There is no appeal. This is worth being precise about, because it is the entire reason this case is a total loss rather than a long wait.
A court judgment can be appealed on the merits — a higher court reads the record and can decide the first one got it wrong. An arbitration award cannot. The only route is a motion to vacate under section 10 of the Federal Arbitration Act, filed in federal district court, and the grounds are procedural:
- The award was procured by corruption or fraud
- An arbitrator was evidently partial or corrupt
- The panel refused to hear material evidence or otherwise mishandled the process
- The arbitrators exceeded their powers
“The panel weighed the damages evidence wrong” is not on that list. A tribunal that weighed the evidence differently than counsel expected hasn’t made a reviewable error — it has made the decision it was appointed to make. Vacatur motions succeed in a low single-digit percentage of attempts, and when they do succeed they usually buy a rehearing in front of a new panel, not a judgment.
There is also a clock. Under section 12, notice of a vacatur motion has to be served within three months of the award, so the window closes around October 28, 2026. That deadline belongs to the claimant, not to me — I have no standing to file anything, and whether they try is their decision and their lawyers’ to make. I’ll find out afterward, the same way I found out about the award.
I’m carrying the position at zero as of the award date. Waiting on a low-probability motion I have no part in is not a valuation.
Timeline
| Date | Event |
|---|---|
| Jul 2008 | License agreement signed |
| Feb 2014 | Licensee terminates the agreement |
| Feb 2015 | Licensee sues first for a declaratory judgment; biotech counterclaims for $900M+ |
| Feb 2016 | Motion to dismiss denied — primary claims survive |
| Apr 2017 | Appeal denied — claims affirmed in their entirety |
| May 2018 | My investment — $75,000 |
| Sep 2019 | Fact discovery closes with nothing adverse |
| Jan 2022 | First mediation fails |
| Aug 2023 | Clinical trials confirm the product reduces antibiotic use |
| Jun 2024 | Second mediation fails |
| Feb 2025 | Case leaves federal court for final and binding arbitration — no appellate tier elected |
| Sep 2025 | Claimant seeks additional financing to pay its own attorneys and experts |
| Jan 2026 | Nine-day evidentiary hearing |
| May 1, 2026 | Closing arguments. Counsel reports the hearing went “very well” |
| ~Jul 1, 2026 | 60-day award deadline passes with no award |
| Jul 28, 2026 | FINAL AWARD for the defendant — claims rejected, $0 |
| Sep 11, 2026 | I find out — six weeks later, in reply to a status request I sent |
| ~Oct 28, 2026 | FAA §12 deadline for any motion to vacate |
Eleven years from the complaint. Eight years and two months from my wire.
What the Offering Said vs. What Happened
| Offering pitch | Reality |
|---|---|
| $900M+ in claimed damages | $0 recovered — the panel rejected the claims outright |
| Documented breaches, not inferred ones | All accurate, and the claims were still rejected in their entirety |
| Claims survived a motion to dismiss and an appeal | Surviving means legally sufficient to be heard, not persuasive to a fact-finder |
| Fortune 50 defendant — no collection risk | True and irrelevant. There was never anything to collect |
| Federal case with a jury and appeal rights | Stipulated into private, final, unappealable arbitration in year seven |
What I Learned
Surviving a motion to dismiss is a floor, not a verdict. The court assumes the plaintiff’s version is true and asks only whether it would state a claim at all. It says nothing about whether the facts can be proved or what they’re worth. It’s the minimum requirement for a case to exist. I had it in the strength column.
Proving a breach and proving what it cost are two different cases. Breach is documentary — meetings, filings, disclosures. Damages on a product that never sold is projection, argued between paid experts. If I haven’t underwritten the second one, I haven’t underwritten the case.
A defendant that won’t settle after discovery is quoting you a price. By 2022 both sides had seen the full record, and a defendant that could have paid anything twice chose not to. That’s worth weighing on a case that comes to you having already been through a failed mediation: it’s the other side’s valuation of the claim, and they’ve read the damages file.
A case can leave court at any time, and it takes the public record with it. The parties can agree to private arbitration years into a federal action, and nobody needs my consent. Seven years of docket I could read myself ended in a single update. What replaces it is whatever the intermediary chooses to send.
“Final and binding” removes the appeal you fear and the one you’d need. Vacatur under FAA §10 reaches fraud, partiality and process failures — never “the panel decided wrong.” Some institutions offer an optional appellate tier; whether the parties elected it is now a question I ask before funding, not after losing.
Counsel’s confidence is an advocate grading his own performance. Nine days in the hearing room makes the read informed, not predictive, and it arrives through a platform that would rather pass along the optimistic version. Fine as colour. The place it does damage is in the offering materials, where it substitutes for a view on the number.
The Final Score
This was my fifth-largest position of the seventeen LexShares cases I funded, and it is now the second-largest loss in the book. The size isn’t the interesting part. What it did to the book’s arithmetic is.
| Resolved book | Invested | Returned | Net |
|---|---|---|---|
| 14 cases, before this award | $820,000 | $849,351 | +$29,351 |
| 15 cases, after | $895,000 | $849,351 | ($45,649) |
One case flipped the entire resolved book from a small gain to a $45,649 loss. Fourteen outcomes — eight of them profitable, several genuinely good — netted to less than a single concentrated position could erase.
That arithmetic isn’t new to me. When I worked through my investor group’s book earlier this year, the finding was that at a 57% win rate the winners have to average about 1.75x just to return the capital, and the platform’s winners came in well under that. My own cases have run at roughly the same win rate. A book whose winners have no margin has no capacity to absorb a total loss. This is what that looks like in practice.
What it didn’t cost me is anything beyond the $75,000. The projected recovery never appeared in a budget, a forecast or a cash-flow plan — it sat outside every base case as optional upside, which is the only sane way to carry a single all-or-nothing claim. Nothing downstream had to be rearranged when it went to zero.
Two cases are still open: $5,000 in an eight-year tribal jurisdiction fight that has already returned $1,791, and $100,000 in a patent case that has survived seven inter partes review petitions. Neither is big enough to bring the resolved book back to even. The LexShares chapter closes at a loss.
Eight years, $900 million claimed, a product that worked, a set of breaches I still believe were real — and the whole thing ended with three people in a private room I’ll never see the transcript of. I spent my diligence on whether the claim was legitimate and none of it on what the claim was worth. The panel ruled on July 28. By the time I heard, six weeks had gone and there was nothing left to decide.
Sources: LexShares case updates from funding through September 2026, including the notice reporting the final award; my own wire and distribution records for the seventeen cases I funded, which are the governing figures here rather than any platform statement; and the arbitral institution’s published rules for the 60-day award deadline. Parties, counsel and the arbitral forum are left unnamed — the underlying contract dispute was litigated publicly, but the arbitration and its award were not. The discussion of vacatur is my reading of Federal Arbitration Act §§ 10 and 12 and is not legal advice; the October date assumes July 28 is also the delivery date of the award.
Commentary and personal experience — not investment, legal, or tax advice. Investing carries risk, including total loss of capital. Always do your own due diligence.
